Last reviewed · How we verify
NCT03509220
Safety and Efficacy of PBK-1701TC for Bowel Cleansing Before Colonoscopy
Phase 3 trial testing PBK-1701TC in Colonic Diseases in 235 participants. Completed in 31 October 2018.
31 October 2018
Quick facts
| Lead sponsor | Pharmbio Korea Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 235 |
| Start date | 11 April 2018 |
| Primary completion | 31 October 2018 |
| Estimated completion | 31 October 2018 |
| Sites | 5 locations across South Korea |
Drugs / interventions tested
- PBK-1701TC — full drug profile →
- Standard oral preparation
Conditions studied
- Colonic Diseases — all drugs for Colonic Diseases →
- Intestinal Disease — all drugs for Intestinal Disease →
- Gastrointestinal Disease — all drugs for Gastrointestinal Disease →
- Digestive System Disease — all drugs for Digestive System Disease →
Sponsor
Pharmbio Korea Co., Ltd. — full company profile →
Who can join
19 and older, any sex, with Colonic Diseases or Intestinal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the efficacy, safety and tolerability of PBK-1701TC for bowel cleansing before colonoscopy. Half the participants will receive PBK-1701TC and while the other will receive standard oral preparation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03509220
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colonic Diseases
Currently open trials in the same condition.
- NCT07351071 — Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Res · NA · recruiting
- NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
- NCT04084249 — ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial · NA · active not recruiting
Other Pharmbio Korea Co., Ltd. trials
Trials by the same sponsor.
- NCT07161180 — Evaluation of the Pharmacokinetics of "PBK_M2301" in Healthy Adults · Phase 1 · recruiting
- NCT07017335 — Drug-Drug Interaction Between R1_PBK_M2301 and R2_PBK_M2301 in Healthy Adults · Phase 1 · completed
- NCT05509868 — Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea · Phase 3 · completed
- NCT04418388 — Pharmacokinetics and Safety of PBK-1801 After Single Oral Administration in Healthy Korean Women · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03509220 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pharmbio Korea Co., Ltd.
- Last refreshed: 26 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03509220.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing